

SUBJECT: Revisions to Sunsetting ACOFP Position Statements of the  
American College of Osteopathic Family Physicians (ACOFP)

SUBMITTED BY: ACOFP Constitution & Bylaws/Policy & Organization Review Committee

REFERRED TO: 2017 ACOFP Congress of Delegates

---

RESOLUTION NO. 3

1 RESOLVED, that Congress of Delegates of the American College of Osteopathic Family Physicians  
2 adopts and approves the sunsetting ACOFP Position Statements as recommended and  
3 submitted by the ACOFP Constitution & Bylaws/Policy & Organization Review Committee.  
4 (Old material crossed out, new material capitalized.)

5  
6 **Coverage for Uninsured and Underinsured Minors**  
7 ***ACTION: RECOMMENDS DELETION, AS ACTION ALREADY HAS TAKEN PLACE.***  
8 The ACOFP encourages its members to urge the U.S. Congress to vote to fully fund an implement  
9 this important health coverage change being proposed for the State Children’s Health Insurance  
10 Program (SCHIP).

11  
12  
13 **Formularies – Physician Consultation**  
14 ***ACTION: RECOMMENDS REAFFIRMATION WITH NO CHANGES.***  
15 The ACOFP supports legislation that requires a physician be available for consultation on  
16 pharmaceutical formulary decisions.

17  
18  
19 **HPV Vaccine Coverage**  
20 ***ACTION: RECOMMENDS REAFFIRMATION WITH NO CHANGES.***  
21 The ACOFP endorses the recommendation of the Advisory Council on Immunization Practices  
22 (ACIP) of the Center for Disease Control (CDC) to provide HPV vaccine to all eligible recipients  
23 and/or be made available through the state department of health.

24  
25  
26 **Transportation Costs for Patients**  
27 ***ACTION: RECOMMENDS REAFFIRMATION WITH NO CHANGES.***  
28 The ACOFP encourage the CMS and third-party payers to develop a policy that pays for appropriate  
29 transportation costs to and from healthcare facilities for those patients at 200 percent of poverty  
30 level or below.

31  
32

33 **Primary Care Incentive Payment**

34 ***ACTION: RECOMMENDS REAFFIRMATION WITH NO CHANGES.***

35 The ACOFP supports a 10% incentive payment to all primary care physicians and Non-Physician  
36 Practitioners (NPPs), who perform Primary Care Services specified in The Affordable Care Act,  
37 Section 5501(a).

38  
39 The ACOFP encourages the United States Congress to instruct the Centers for Medicare & Medicaid  
40 Services (CMS) to change the existing qualifications in the Affordable Care Act for the 10% incentive  
41 payment by eliminating the Physician's Primary Care Incentive Percentage, thereby including all  
42 primary care physicians and non-physician practitioners who perform the specified primary care  
43 services.

44

45

46 **Texting While Driving**

47 ***ACTION: RECOMMENDS DELETION. THIS POLICY DUPLICATES EXISTING POLICY, "USE OF***  
48 ***ELECTRONIC DEVICES WHILE DRIVING."***

49 The ACOFP opposes texting while operating motorized vehicles.

50

51

52 **Certification**

53 ***ACTION: RECOMMENDS REAFFIRMATION WITH EDITORIAL CHANGES.*** The ACOFP **CONTINUES**  
54 **TO** recognizes those physicians certified through the clinical pathway as holding board certification  
55 equivalent to certification achieved through residency training. When necessary, the ACOFP,  
56 working with the AOA, shall educate healthcare institutions and managed care programs on this  
57 issue.

58

59

60 **Certification - COM Chairs**

61 ***ACTION: RECOMMENDS REAFFIRMATION WITH NO CHANGES.***

62 The ACOFP requests COCA (Commission on Osteopathic College Accreditation) to amend the  
63 accreditation requirements for colleges of osteopathic medicine to state that chairs of the  
64 departments of family medicine at colleges of osteopathic medicine be AOA certified and be  
65 members in good standing with the ACOFP/AOA.

66

67

68 **Soft Drinks in Schools**

69 ***ACTION: RECOMMENDS REAFFIRMATION WITH NO CHANGES.***

70 ACOFP members shall educate and caution their adolescent patients, school superintendents, and  
71 members of school boards across our nation as to the health consequences of soft drinks, and urge  
72 them to restrict sales of non-nutritional drinks. ACOFP supports the efforts of some of the soft  
73 drink producers that have already taken the initiative to provide and process more nutritious  
74 beverages.

75

76 **Tissue and Organ Donation Education**

77 ***ACTION: RECOMMENDS REAFFIRMATION WITH NO CHANGES.***

78 The ACOFP members are encouraged to provide educational materials to families, friends, and  
79 patients about tissue and organ donation programs.

80

81 **Use of Electronic Devices While Driving**

82 ***ACTION: RECOMMENDS REAFFIRMATION WITH NO CHANGES.***

83 The ACOFP opposes texting while operating motorized vehicles.

84

85 **Prescription Pain Medication/Long-Acting Opioid Medication**

86 ***ACTION: RECOMMENDS REAFFIRMATION WITH NO CHANGES.***

87 It is a basic right of all patients to receive adequate control of acute and chronic pain. It is a primary  
88 duty of all physicians, regardless of specialty, to provide medication and modalities that will achieve  
89 safe and effective pain control for all their patients.

90

91 As patient advocates and physicians, we believe that it is in the best interest of all patients not to  
92 confine, or seek to regulate opioid medications by limiting their use to a small number of selected  
93 specialties of medicine. This would also extend to newer modalities now developed, or yet to be  
94 developed, such as long-acting opioid preparations. These exclusionary strategies will limit access  
95 for patients with medical indications for therapy, complicate delivery of care, and add to pain and  
96 suffering of patients in all areas of our country.

97

98 We support the voluntary universal education of all physicians, as well as others involved in the  
99 management of pain patients, on the proper diagnosis and appropriate treatment of pain. A well-  
100 educated, physician-led team of health care providers, following scientifically-established  
101 treatment protocols, will not only deliver quality care, but will be sensitive to the problems of  
102 addiction and diversion of prescription pain medication.

103

104 **Ambulatory-Based Family Medicine Residency Programs**

105 ***ACTION: RECOMMENDS REAFFIRMATION WITH EDITORIAL CHANGES.***

106 The ACOFP supports and advocates for development and implementation of **MORE** ambulatory-  
107 based family medicine residency programs.

108

109 The ACOFP encourages the United States Congress to strengthen its Graduate Medical Education  
110 reimbursement policies to at least equivalently fund ambulatory-based family medicine residency  
111 programs.

112

113 The ACOFP encourages the AOA to **CONTINUE TO** lobby the United States Congress to support  
114 legislation funding ~~demonstration models~~ of ambulatory-based family medicine residency  
115 programs.

116 **Human Genome Project**

117 ***ACTION: RECOMMENDS REAFFIRMATION WITH NO CHANGES.***

118 ***Explanatory Statement: The ACOFP agrees with the policy but will work to rewrite a more***  
119 ***concise policy accompanied by a whitepaper.***

120

121 **Background**

122 In the late 1980's the U.S. Department of Energy, in cooperation with the National Institutes of  
123 Health, initiated a research project that would grow into the Human Genome Project in 1990. The  
124 Human Genome Project was sponsored by an agency formed for this purpose, the National Human  
125 Genome Research Institute (NHGRI). Despite initial doubts from many sides an optimistic goal was  
126 set to decipher the genetic code of Homo sapiens by the year 2005. Today we know that this goal  
127 was not too ambitious and an initial map of the human genome was actually achieved in the year

128 2000 and, in an improved version, was published publicly in February of 2001. The next  
129 challenges will lie in interpreting the information and relating it to human health and disease.

130  
131 The initial goals of the Human Genome Project were: 1. Construction of a high-resolution genetic  
132 map of the human genome, 2. Production of a variety of physical maps of all human chromosomes  
133 and of the DNA of selected model organisms, with emphasis on maps that make the DNA accessible  
134 to investigators for further analysis. This series of maps would be of increasingly fine resolution,  
135 and 3. Determination of the complete sequence of human DNA and DNA of selected model  
136 organisms. With these goals apparently well in sight there are a multitude of ambitious new  
137 objectives springing up in both the scientific and medical/industrial communities such as these  
138 listed below (quoted from the U.S. Department of Energy Office of Science, Office of Biological and  
139 Environmental Research, Human Genome Program):

140  
141 **Molecular Medicine**  
142 Improve diagnosis of disease; detect genetic predispositions to disease; create drugs based on  
143 molecular information; use gene therapy and control systems as drugs; and design "custom drugs"  
144 based on individual genetic profiles

145  
146 **Microbial Genomics**  
147 Rapidly detect and treat pathogens (disease-causing microbes) in clinical practice; develop new  
148 energy sources (biofuels); monitor environments to detect pollutants; protect citizenry from  
149 biological and chemical warfare; and clean up toxic waste safely and efficiently

150  
151 **Risk Assessment**  
152 Evaluate the health risks faced by individuals who may be exposed to radiation (including; low  
153 levels in industrial areas) and to cancer-causing chemicals and toxins; bio archaeology,  
154 Anthropology, Evolution, and Human Migration; study evolution through germ line mutations in  
155 lineages; study migration of different population groups based on maternal genetic inheritance;  
156 study mutations on the Y chromo; some to trace lineage and migration of males; and compare  
157 breakpoints in the evolution of mutations with ages of populations and historical events

158  
159 **DNA Identification**  
160 Identify potential suspects whose DNA may match evidence left at crime scenes; exonerate persons  
161 wrongly accused of crimes; identify crime, catastrophe, and other victims; establish paternity and  
162 other family relationships; identify endangered and protected species as an aid to wildlife officials  
163 (could be used for prosecuting poachers); detect bacteria and other organisms that may pollute air,  
164 water, soil, and food; match organ donors with recipients in transplant programs; determine  
165 pedigree for seed or livestock breeds; and authenticate consumables such as caviar and wine.

166  
167 **Agriculture, Livestock Breeding, and Bioprocessing**  
168 Grow disease-, insect-, and drought-resistant crops; breed healthier, more productive, disease-  
169 resistant farm animals; grow more nutritious produce; develop bio pesticides; incorporate edible  
170 vaccines into food products; and develop new environmental cleanup uses for plants like tobacco.  
171 In addition, many ethical, legal and social issues (ELSI) have been identified in relation to the  
172 Human Genome Project. The involvement of the private sector in the "race" to discover the genome  
173 adds another concern as there is considerable opportunity for unforeseen difficulties if proprietary  
174 concerns encroach on the project; some groups now working on sequencing are completely  
175 commercial and plan to release information only in patent applications. Because of these risks, the

176 Human Genome Project has dedicated a significant portion of its budget to examining ELSI issues as  
177 evidenced by this text from "New Goals for the U.S. Human Genome Project: 1998-2003," Science  
178 282: 682 - 689 (1998) which details some of the goals of the project: Examine issues surrounding  
179 the completion of the human DNA sequence and the study of human genetic variation; examine  
180 issues raised by the integration of genetic technologies and information into health care and public  
181 health activities; examine issues raised by the integration of knowledge about genomics and gene-  
182 environment interactions in non-clinical settings; explore how new genetic knowledge may interact  
183 with a variety of philosophical, theological, and ethical perspectives; explore how racial, ethnic, and  
184 socioeconomic factors affect the use, understanding, and interpretation of genetic information; the  
185 use of genetic services; and the development of policy.

186

187 Recognized concerns arising from this project include:

188 A.) Fairness in the use of genetic information by insurers, employers, courts, schools, adoption  
189 agencies, and the military, among others.

190 Who should have access to personal genetic information, and how will it be used?

191

192 B.) Privacy and confidentiality of genetic information.

193 Who owns and controls genetic information?

194

195 C.) Psychological impact and stigmatization due to an individual's genetic differences.

196 How does personal genetic information affect an individual and society's perceptions of that  
197 individual?

198 How does genomic information affect members of minority communities?

199

200 D.) Reproductive issues including adequate informed consent for complex and potentially  
201 controversial procedures, use of genetic information in reproductive decision making, and  
202 reproductive rights.

203 Do healthcare personnel properly counsel parents about the risks and limitations of genetic  
204 technology?

205 How reliable and useful is fetal genetic testing?

206 What are the larger societal issues raised by new reproductive technologies?

207

208 E.) Clinical issues including the education of doctors and other health service providers, patients,  
209 and the general public in genetic capabilities, scientific limitations, and social risks; and  
210 implementation of standards and quality-control measures in testing procedures.

211

212 F.) How will genetic tests be evaluated and regulated for accuracy, reliability, and utility?

213 (Currently, there is little regulation at the federal level.)

214 How do we prepare healthcare professionals for the new genetics?

215 How do we prepare the public to make informed choices?

216 How do we as a society balance current scientific limitations and social risk with long-term  
217 benefits?

218

219 G.) Uncertainties associated with gene tests for susceptibilities and complex conditions (e.g., heart  
220 disease) linked to multiple genes and gene-environment interactions.

221 Should testing be performed when no treatment is available?

222 Should parents have the right to have their minor children tested for adult-onset diseases?

223 Are genetic tests reliable and interpretable by the medical community?

224 H.) Conceptual and philosophical implications regarding human responsibility, free will vs. genetic  
225 determinism, and concepts of health and disease.  
226 Do people's genes make them behave in a particular way?  
227 Can people always control their behavior?  
228 What is considered acceptable diversity?  
229 Where is the line between medical treatment and enhancement?  
230

231 I.) Health and environmental issues concerning genetically modified foods (GM) and microbes.  
232 Are GM foods and other products safe to humans and the environment?  
233 How will these technologies affect developing nations' dependence on the West? J.  
234 Commercialization of products including property rights (patents, copyrights, and trade secrets)  
235 and accessibility of data and materials.  
236 Who owns genes and other pieces of DNA?  
237 Will patenting DNA sequences limit their accessibility and development into useful products?  
238

### 239 Introduction

240 The vast potential for good and for harm of the Human Genome Project requires an organization  
241 such as ours, which shares the responsibility for health care delivery in this nation, to participate in  
242 the vigilance demanded of these possibilities. Monitoring even the few aspects of the project  
243 mentioned above would create an enormous task that could easily consume all the resources of the  
244 ACOFP, nevertheless we do share an obligation to our members and to the public to carry a realistic  
245 burden of watchfulness and caution. It is our duty to promptly incorporate tested and accepted  
246 therapies as they are developed. It is our duty to sound the alarm when we see our patients  
247 become victims instead of beneficiaries of these technologies.  
248

### 249 Recommended Actions

250 The ACOFP Board of Governors, through its members, committees, and staff shall take appropriate  
251 action in each of these areas:  
252

#### 253 A.) Education

254 The ACOFP shall support education regarding the Human Genome Project at all levels (practicing  
255 physicians, resident physicians and student physicians).  
256

#### 257 B.) Legislation

258 The ACOFP shall monitor governmental actions, legislation and intent in regulating the Human  
259 Genome Project. The ACOFP shall be proactive in raising the voice of the ACOFP when threats to  
260 the implementation or threats from the implementation of the Human Genome Project are  
261 identified. The ACOFP should attempt to influence state legislatures and state societies to take  
262 stands in their own legislatures.  
263

#### 264 C.) Ethical, Legal, and Social Issues (ELSI)

265 As osteopathic family practice physicians we are often among the first to recognize potential for  
266 harm to our patients and to our profession. The ACOFP shall take a strong stand whenever it finds  
267 evidence of risk to the health or well-being of our patients as a consequence of the ethical, legal, or  
268 societal applications of this knowledge and technology.  
269  
270  
271

272 **Team Physician Definition**

273 ***ACTION: RECOMMENDS REAFFIRMATION WITH NO CHANGES.***

274 The team physician must have an unrestricted medical license and be a DO or MD who is  
275 responsible for treating and coordinating the medical care of athletic team members. The principal  
276 responsibility of the team physician is to provide for the well-being of individual athletes – enabling  
277 each to realize his/her full potential. The team physician should possess special proficiency in the  
278 care of musculoskeletal injuries and medical conditions encountered in sports. The team physician  
279 also must actively integrate medical expertise with other healthcare providers, including medical  
280 specialists, athletic trainers, and allied health professionals. The team physician must ultimately  
281 assume responsibility within the team structure for making medical decisions that affect the  
282 athlete's safe participation.

283  
284 **Qualifications of a Team Physician**

285 The primary concern of the team physician is to provide the best medical care for athletes at all  
286 levels of participation. To this end, the following qualifications are necessary for all team  
287 physicians: possess a DO or MD degree as a licensed physician in good standing, with an  
288 unrestricted license to practice medicine; possess a fundamental knowledge of emergency care  
289 regarding sporting events; be trained in CPR; and have a working knowledge of trauma,  
290 musculoskeletal injuries, and medical conditions affecting the athlete.

291  
292 In addition, it is desirable for team physicians to have clinical training/experience and  
293 administrative skills in some or all of the following: specialty board certification; continuing  
294 medical education in sports medicine; formal training in sports medicine (fellowship training), or  
295 board recognized subspecialty in sports medicine (formerly known as a certificate of added  
296 qualification in sports medicine); additional training in sports medicine; fifty percent or more of  
297 practice involving sports medicine; membership and participating in a sports medicine society;  
298 involvement in teaching, research and publications relating to sports medicine; training in  
299 advanced cardiac life support; knowledge of medical/legal, disability, and workers' compensation  
300 issues; and media skills training.

301  
302 **Duties of a Team Physician**

303 The team physician must be willing to commit the necessary time and effort to provide care to the  
304 athlete and team. In addition, the team physician must develop and maintain a current, appropriate  
305 knowledge base of the sport(s) for which he/she is accepting responsibility.

306  
307 The duties for which the team physician has ultimate responsibility include the following: medical  
308 management of the athlete; coordinate pre-participating screening, examination, and evaluation;  
309 manage injuries on the field; provide for medical management of injury and illness; coordinate  
310 rehabilitation and return to participation; provide for proper preparation for safe return to  
311 participation after an illness or injury; integrate medical expertise with other health care providers,  
312 including medical specialists, athletic trainers and allied health professionals; provide for  
313 appropriate education and counseling regarding nutrition, strength and conditioning, substance  
314 abuse, and other medical problems that could affect the athlete; and provide for proper  
315 documentation and medical record keeping.

316  
317 **Administrative and Logistical Duties**

318 The administrative and logistical duties of the team physician include: establish and define the  
319 relationships of all involved parties; educate athletes, parents, administrators, coaches, and other

320 necessary parties of concerns regarding the athletes; develop a chain of command; plan and train  
321 for emergencies during competition and practice; address equipment and supply issues; provide for  
322 proper event coverage; and assess environmental concerns and playing conditions.

323  
324 Education of a Team Physician  
325 Ongoing education pertinent to the team physician is essential. Currently, there are several state,  
326 regional and national stand-alone courses for team physician education and there are also many  
327 other resources available. Information regarding team physician specific educational opportunities  
328 can be obtained from the following sport specific organizations: National Football League Team  
329 Physician's Society or level-specific (e.g., United States Olympic Committee meetings; National  
330 Governing Bodies' (NGB) meetings; state and/or county medical societies meetings; professional  
331 journals; and other relevant electronic media.

332  
333 Conclusion  
334 The Consensus Statement establishes a definition of the team physician, and outlines a team  
335 physician's qualification and responsibilities. It also contains strategies for the continuing  
336 education of team physicians. Ultimately, this statement provides guidelines that best serve the  
337 health care needs of athletes and teams.

338  
339 **Non-Physician Clinicians**  
340 ***ACTION: RECOMMENDS REAFFIRMATION WITH NO CHANGES.***  
341 The AOA Policy Statement on Non-Physician Clinicians shall be adopted as ACOFP Policy on Non-  
342 Physician Clinicians:  
343 The practice of medicine and the quality of medical care are the responsibility of properly licensed  
344 physicians. As the DO/MD medical model has proven its ability to provide professionals with  
345 complete medical education and training, their leadership in such an approach is logical and most  
346 appropriate. Public policy dictates patient safety and proper patient care should be foremost in  
347 mind when the issues encompassing expanded practice rights for non-physician clinicians –  
348 autonomy, scopes of practice, prescriptive rights, liability and reimbursement, among others – are  
349 addressed.

350  
351 Patient Safety  
352 The AOA supports the "team" approach to medical care, with the physician as the leader of that  
353 team. The AOA further supports the position that patients should be made clearly aware at all  
354 times whether they are being treated by a non-physician clinician or a physician. The AOA  
355 recognizes the growth of non-physician clinicians and supports their rights to practice within the  
356 scope of the relevant state statutes. However, it is the AOA's position that new roles for non-  
357 physician clinicians may be granted after appropriate processes and programs are established in all  
358 of the following four areas: education, training, examination, and regulation. It is further the AOA's  
359 stance that non-physician clinicians may be allowed to expand their rights only after it is proven  
360 they have the ability to provide healthcare within these new roles safely and effectively.

361  
362 Independent Practice  
363 It is the AOA's position that roles within the "team" framework must be clearly defined, through  
364 established protocols and signed agreements, so physician involvement in patient care is sought  
365 when a patient's case dictates. The AOA feels non-physician clinician professions that have  
366 traditionally been under the supervision of physicians must retain physician involvement in patient  
367 care. Those non-physician clinician professions that have traditionally remained independent of

368 physicians must involve physicians in patient care when warranted. All non-physician clinicians  
369 must refer a patient to a physician when the patient's condition is beyond the non-physician  
370 clinician's scope of expertise.

371  
372 **Liability**  
373 The AOA endorses the view that physician liability for non-physician clinician actions should be  
374 reflective of the quality of supervision being provided and should not exonerate the non-physician  
375 clinician from liability. It is the AOA's position that non-physician clinicians acting autonomously of  
376 physicians should be held to the equivalent degree of liability as that of a physician. Within this  
377 independent practice framework, the AOA further believes that non-physician clinicians should be  
378 required to obtain malpractice insurance in those states that currently require physicians to  
379 possess malpractice insurance.

380  
381 **Educational Standards**  
382 DO's/MD's have proven and continue to prove the efficacy of their education, training,  
383 examinations, and regulation for the unlimited practice of medicine and it is the AOA's firm  
384 conviction that only holders of DO and MD degrees be licensed for medicine's unlimited practice.  
385 The osteopathic profession has continually proven its ability to meet and exceed standards  
386 necessary for the unlimited practice of medicine, as non-physician clinicians seek wider roles,  
387 standards of education, training, examination, and regulation must all be adopted to protect the  
388 patient and ensure that proper patient care is being given. The AOA holds the position that  
389 education, training, examination and regulation must all be documented and reflective of the  
390 expanded scopes of practice being sought by non-physician clinicians. The AOA recognizes there  
391 may be a need for an objective, independent body to review and validate non-physician clinician  
392 standards.

393  
394 *H228-A/05 NON-PHYSICIAN CLINICIANS: The American Osteopathic Association has adopted the*  
395 *above policy as its position on non-physician clinicians including appropriate onsite supervision. 2000,*  
396 *Revised 2005; Revised 2010.*

397 Receivers of health care should also be advised of the education and training of the PA or NP. At no  
398 time should those persons be completely independent of supervision from a fully-licensed  
399 physician, in compliance with state law. Any severe or complicated medical or surgical case should  
400 be brought to the attention of their supervising physician as soon as possible.

401  
402 Each PA or NP should carry their own professional liability insurance independent of their  
403 employer subject to state law. We realize that many osteopathic/allopathic physicians are  
404 employer/supervisors of PAs or NPs. The objective of this position paper is to ensure safe and  
405 effective care of the highest quality for their patients.

406  
407 **FINAL ACTION: APPROVED as of MARCH 16, 2017**